Implications of using modification of diet in renal disease versus Cockcroft-Gault equations for renal dosing adjustments.
The drug-dosing implications of using modification of diet in renal disease (MDRD) versus Cockcroft-Gault equations were analyzed. This retrospective, cohort-controlled study evaluated the implications of using MDRD versus Cockcroft-Gault equations for renal dosing adjustments in patients with stage III-V chronic kidney disease. Dosing simulations were completed for each patient using both MDRD and Cockcroft-Gault methods and then compared to published manufacturer dosing recommendations. Bland-Altman analysis assessed agreement of MDRD and Cockcroft-Gault estimates. Contingency tables were used to evaluate the clinical relevance of dosing adjustments in terms of medication overdoses and underdoses. Data from 4698 patients with stage III-V chronic kidney disease were analyzed. Use of the MDRD equation overestimated the need for dosing adjustments for patients with creatinine clearance (CL(cr)) values of <30 mL/min/1.73 m(2) and underestimated the need for patients with a CL(cr) of >50 mL/min/1.73 m(2). For medication-dosing thresholds, MDRD was associated with an underdose rate of 7.3% and an overdose rate of 9.6% (p < 0.01 for both). For MDRD adjustments within medication-dosing ranges, both overdoses and underdoses occurred in up to 12.4% (p < 0.01). Total dosing errors for MDRD ranged from 9.8% to 18.2%, depending on the medication (p < 0.01). Significant variability exists between the MDRD and Cockcroft-Gault equations for spot dosing adjustments. Use of MDRD estimates with current manufacturer dosing guidelines may result in subtherapeutic medication therapies for patients with stage IV or V disease and supratherapeutic therapies for patients with stage III disease.